Loading clinical trials...

Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma | Clinical Trials | Clareo Health

UNKNOWNPHASE2

Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma

Open-label, Multi-center Phase IIa Study to Evaluate the Efficacy, Safety, and Immunological Response of OBP-301, Telomerase Specific Replication-competent Oncolytic Adenovirus in Patients With Unresectable Metastatic Melanoma

NCT03190824•Syneos Health

View on ClinicalTrials.gov

Summary

Open-label, single-arm, multi-center, Phase IIa study to evaluate the efficacy, safety, and immunological response of OBP 301 in patients with unresectable/unresected metastatic melanoma. This proof of concept study will be undertaken in male and female patients with unresectable Stage III and IV melanoma. Patients with unresectable/unresected mucosal melanoma may be enrolled after consultation with the Medical Monitor.

Detailed Description

Primary Objective: The primary objective of this study is to evaluate the overall tumor sites response (objective response rate \[ORR\]) to OBP-301 in both injected and noninjected lesions up to and including Week 24 in patients with unresectable/unresected Stage III and IV melanoma. The ORR is defined as the rate of complete response (CR) and partial response (PR) based on the modified immune-related response criteria (irRC) 1.0. The modification is to allow the identification of up to 10 cutaneous, subcutaneous, and/or lymph node tumor lesions and identify the lesions as target and nontarget lesions. Secondary Objectives: * To evaluate the ORR up to and including Week 24 in injected target lesions based on the modified irRC 1.0 and Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 * To evaluate the ORR up to and including Week 24 in noninjected target lesions based on modified irRC 1.0 and RECIST 1.1 * To evaluate the ORR in both injected and noninjected target lesions at Week 12 based on the modified irRC 1.0 and RECIST 1.1 * To evaluate duration of response and time to response * To evaluate progression free survival (PFS) at Week 24 and Week 48 * To evaluate overall survival (OS) at Week 24 and Week 48 * To evaluate the safety of OBP 301 Exploratory Objective (optional): The optional exploratory objective of this study is to investigate the tumor immunological response in blood and tumor tissue following treatment with OBP-301.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Histologically or cytologically confirmed malignant melanoma at Screening that is unresectable/unresected Stage IIIB, IIIC, IIID or IV. Patients with unresectable mucosal melanoma may be enrolled after consultation with the Medical Monitor.
•2. Patients must have received and failed or refused available therapy for unresectable/unresected Stage III or IV melanoma.
•3. Patients must be ≥ 18 years of age.
•4. At least 2 cutaneous, subcutaneous and/or lymph node target lesions that are greater or equal to 1 cm in the longest diameter. One of the cutaneous, subcutaneous and/or lymph node target lesions should be designated at Screening as a noninjected target lesion. Willing to have biopsy specimens taken at Screening and at Week 6.
•5. Life expectancy of ≥ 6 months from the first OBP-301 treatment.
•6. Karnofsky Performance Status Scale (KPS) score of ≥ 70.
•7. Adequate organ function, hematologic status, coagulation status, kidney function, and liver function as follows:
•* Absolute neutrophils \> 1,500/µL
•* Hemoglobin \> 9 g/dL, without transfusion or hematopoietic growth factor
•* Platelets \> 100,000/µL. Patients with ≤ 100,000 platelet count may be allowed into the study on a case-by-case basis after consultation with the Medical Monitor.
+6 more criteria

Exclusion Criteria

•1. Patients who have had administration of chemotherapy, target therapy, and/or immunotherapy within the last 4 weeks before the first OBP-301 administration.
•2. Patients who have received other investigational medication within the last 4 weeks or a period of its 5 half-lives (whichever is shorter) before the first OBP-301 administration.
•3. Patients who have had radiotherapy within the last 4 weeks before the first OBP-301 administration.
•4. Effects of any other prior therapies not reverted to ≤ Grade 1 (or ≤ Grade 2 for alopecia and peripheral neuropathy).
•5. Patients who have any liver metastases or visceral metastasis of ≥ 3 cm, plus evidence of progression meeting irRC 1.0 within 1 month before the first OBP-301 administration.
•6. Patients with clinically active brain metastases. However, patients with previously currently stable brain metastases on medication (i.e., steroids and/or anti-seizure medications) may be enrolled after consultation with the Medical Monitor.
•7. Patients known to have acute or chronic active hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV).
•8. Patients diagnosed with additional malignancy within 3 years before the first OBP-301 administration with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or curatively resected in situ cervical and/or breast cancers.
•9. Patients requiring chronic systemic immunosuppressive medication including pharmacologic dose of glucocorticoids or cyclosporine should be evaluated by the Medical Monitor for enrollment eligibility.
•10. Uncontrolled intercurrent illness including, but not limited to, uncontrolled diabetes, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/psychological incompetence, whereby in the opinion of the Investigator the patient is assessed as being unable to provide information, consent, or comply with the study requirements and procedures.
+1 more criteria

Locations (1)

Research Site

Morristown, New Jersey, United States

Key Dates

Start Date

December 22, 2016

Primary Completion Date

June 24, 2021

Completion Date

October 31, 2021

Last Updated

April 16, 2019

Enrollment

ACTUAL participants

Conditions

Melanoma Stage IIIMelanoma Stage Iv

Interventions

OBP-301

DRUG

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

NCT04562129

Melanoma Stage IIIMelanoma Stage IV+1 more

View study

RECRUITINGPHASE1/PHASE2

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

NCT05970497

CancerMelanoma Stage III+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 16, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma

Inclusion Criteria

Exclusion Criteria

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

Observational Study of Patients With Advanced Melanoma (Skin Cancer) to Assess if IOpener®-Melanoma Test Can Predict Response to Immunotherapy.

Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment

CARDiac Toxicity Following ImmunOtherapy Treatment for Melanoma

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis